The Human Immunoglobulin (pH4) for Intravenous Injection Market Propelled by Increased Prevalence of Immunodeficiency Diseases



Human immunoglobulin (pH4) for intravenous injection contains antibodies (immunoglobulin) extracted and purified from the plasma of human blood donors. It is used to treat various immunodeficiency diseases and related conditions. The intravenous route delivers high doses of immunoglobulin directly in the bloodstream allowing for rapid distribution of antibodies to various body tissues.

The global Human immunoglobulin (pH4) for intravenous injection market is estimated to be valued at US$ 2,055.76 Mn in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The increasing prevalence of immunodeficiency diseases has been a major factor driving the growth of the Human Immunoglobulin (pH4) for Intravenous Injection Market. According to expert estimations, every year about 1 in 1200 babies is born with some form of Primary immunodeficiency. Primary immunodeficiencies include conditions such as combined immunodeficiency, phagocytic disorders including chronic granulomatous disease, complement deficiencies and others. Secondary immunodeficiencies acquired later in life like HIV/AIDS and due to chemotherapy or radiation treatment for cancers also require lifelong immunoglobulin replacement therapy. Added to it, rising awareness regarding available treatment options for immunodeficiencies and growing healthcare expenditure in emerging nations are some other factors expected to fuel the demand for intravenous immunoglobulin over the forecast period.

SWOT Analysis
Strength: Human Immunoglobulin (pH4) for Intravenous Injection serves as an important treatment option for various diseases. It helps strengthen the body’s defense mechanisms.
Weakness: High costs associated with R&D, clinical trials, and production of Human Immunoglobulin (pH4) for Intravenous Injection. Risk of side effects.
Opportunity: Rising prevalence of immunodeficiency diseases and growing geriatric population presents an opportunity. Untapped emerging markets offer potential for growth.
Threats: Stringent regulations associated with production and approval. Threat of substitute therapies eating into market share.

Key Takeaways
The global Human Immunoglobulin (pH4) for Intravenous Injection market is expected to witness high growth.

North America dominates the global market and is expected to continue its dominance over the forecast period owing to increasing research funding and rising prevalence in the United States. Asia Pacific is expected to witness the fastest growth during the forecast period owing to expansion of private-sector hospitals and increasing awareness about immunodeficiency diseases.

Key players
Key players operating in the Human Immunoglobulin (pH4) for Intravenous Injection market are Major players operating in the point of care infectious disease diagnostics market include Danaher Corporation, Abbott Laboratories, Alcon Laboratories, Inc., Hoffman-La Roche Ltd., Becton, Dickinson, and Company, Trinity Biotech Plc, AccuBioTech Co., Ltd. and Cardinal Health, Inc. These key players are involved in new product launches, collaborations and acquisitions to gain market share.


1.      Source: Coherent Market Insights, Public sources, Desk research
2.      We have leveraged AI tools to mine information and compile it